Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) today announced that it has launched the sale of Trastuzumab BS for I.V. Infusion 60mg “NK” ・150mg “NK”(hereinafter referred to as “Trastuzumab BS “NK”).
Trastuzumab BS “NK” is a biosimilar of the trastuzumab humanized anti-human HER2 monoclonal antibody. In this March, Nippon Kayaku obtained the manufacture and marketing approval with the indication of advanced or recurrent gastric cancer overexpressing HER2. Celltrion group has already received approvals in EU and Korea. Nippon Kayaku began development of Trastuzumab BS “NK” in November 2010 according to a cooperation agreement with the Celltrion group.
Trastuzumab BS “NK” is the second monoclonal antibody biosimilar for Nippon Kayaku following Infliximab BS for I.V. Infusion 100mg “NK”. With the marketing of Trastuzumab BS “NK”, we expect to make a significant contribution to the patients, their families and medical professionals.
